Evaxion biotech reports data from phase 1/2a trials of evx-01 and evx-02

Copenhagen, denmark, july 08, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotech company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today results from both its phase 1/2a trial of cancer immunotherapy evx-01 in metastatic melanoma and interim phase 1/2a trial of cancer immunotherapy evx-02 in adjuvant melanoma.
EVAX Ratings Summary
EVAX Quant Ranking